The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

THRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 46.70%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Theseus Pharmaceuticals Insider Trading History Chart

Theseus Pharmaceuticals Share Price & Price History

^$4.06

+0.30 (1.20%)

As of 02/14/2024 01:00 AM ET

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

From Weiss Ratings | Ad

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Theseus Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2023	Carl L. Gordon	Director	Buy	479,932	$3.05	$1,463,792.60	17,063,000
7/17/2023	Foresite Capital Management V,	Major Shareholder	Buy	700,000	$2.97	$2,079,000.00	4,108,796
11/30/2022	Bradford D. Dahms	CFO	Buy	1,502	$6.66	$10,003.32	6,142
11/7/2022	Carl L. Gordon	Director	Buy	192,000	$5.21	$1,000,320.00	16,734,518
1/21/2022	Carl L. Gordon	Director	Buy	111,896	$9.97	$1,115,603.12
1/19/2022	Carl L. Gordon	Director	Buy	11,521	$9.97	$114,864.37
1/13/2022	Carl L. Gordon	Director	Buy	17,320	$9.43	$163,327.60
1/11/2022	Carl L. Gordon	Director	Buy	8,500	$10.51	$89,335.00
12/21/2021	Bradford D. Dahms	CFO	Buy	1,970	$10.15	$19,995.50
12/21/2021	Timothy P. Clackson	CEO	Buy	2,600	$9.76	$25,376.00

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

SEC Filings (Institutional Ownership Changes) for Theseus Pharmaceuticals (NASDAQ:THRX)

91.05% of Theseus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Theseus Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/15/2024	Frazier Life Sciences Management L.P.	2,118,051	$8.58M	0.5%	-5.8%	4.789%
2/15/2024	Beryl Capital Management LLC	288,887	$1.17M	0.6%	N/A	0.653%
2/14/2024	ADAR1 Capital Management LLC	174,715	$0.71M	0.3%	N/A	0.395%
2/13/2024	Tower Research Capital LLC TRC	9,302	$38K	0.0%	+62.2%	0.021%
2/12/2024	MMCAP International Inc. SPC	277,303	$1.12M	0.2%	N/A	0.627%
2/12/2024	Highbridge Capital Management LLC	616,860	$2.50M	0.1%	N/A	1.395%
2/6/2024	AJOVista LLC	9,520	$39K	0.0%	N/A	0.022%
2/2/2024	BML Capital Management LLC	1,108,320	$4.49M	3.4%	N/A	2.506%
1/30/2024	BML Capital Management LLC	1,108,317	$4.49M	3.5%	N/A	2.506%
1/30/2024	Strs Ohio	46,300	$0.19M	0.0%	+1,614.8%	0.105%
1/19/2024	Denali Advisors LLC	103,800	$0.42M	0.1%	-18.8%	0.235%
1/12/2024	SG Americas Securities LLC	13,212	$54K	0.0%	N/A	0.030%
1/5/2024	Exchange Traded Concepts LLC	48,510	$0.20M	0.0%	+34.0%	0.110%
11/15/2023	Laurion Capital Management LP	171,157	$0.46M	0.0%	-4.7%	0.393%
11/15/2023	Affinity Asset Advisors LLC	400,726	$1.08M	0.3%	+66.8%	0.919%
11/14/2023	Lynx1 Capital Management LP	702,415	$1.89M	1.2%	-7.2%	1.611%
11/13/2023	Foresite Capital Management V LLC	4,108,796	$11.05M	17.6%	+14.6%	9.424%
11/13/2023	Acadian Asset Management LLC	259,470	$0.70M	0.0%	N/A	0.595%
11/8/2023	Forefront Analytics LLC	17,672	$48K	0.0%	N/A	0.041%
10/27/2023	TD Asset Management Inc	213,896	$0.58M	0.0%	+100.0%	0.491%
10/20/2023	Denali Advisors LLC	127,900	$0.34M	0.1%	+675.2%	0.293%
10/18/2023	Exchange Traded Concepts LLC	36,210	$97K	0.0%	+144.8%	0.083%
8/21/2023	Affinity Asset Advisors LLC	240,244	$2.24M	0.8%	+144.6%	0.551%
8/15/2023	HighVista Strategies LLC	136,719	$1.28M	0.6%	N/A	0.314%
8/14/2023	Driehaus Capital Management LLC	232,693	$2.17M	0.0%	+2.9%	0.534%
8/8/2023	Candriam S.C.A.	270,015	$2.52M	0.0%	-16.6%	0.620%
8/7/2023	Principal Financial Group Inc.	10,679	$100K	0.0%	N/A	0.025%
8/2/2023	Bank of Montreal Can	277,074	$2.80M	0.0%	N/A	0.636%
7/20/2023	Exchange Traded Concepts LLC	14,791	$0.14M	0.0%	N/A	0.034%
7/18/2023	Denali Advisors LLC	16,500	$0.15M	0.1%	N/A	0.038%
5/16/2023	Fairmount Funds Management LLC	1,865,671	$16.57M	2.8%	N/A	4.281%
5/16/2023	Altium Capital Management LP	112,614	$1M	0.6%	N/A	0.258%
5/16/2023	Boxer Capital LLC	350,000	$3.11M	0.2%	-15.7%	0.803%
5/15/2023	Affinity Asset Advisors LLC	98,221	$0.87M	0.3%	N/A	0.225%
5/10/2023	Tekla Capital Management LLC	75,000	$0.67M	0.0%	-25.0%	0.172%
5/3/2023	Jump Financial LLC	15,859	$0.14M	0.0%	N/A	0.036%
2/14/2023	Boxer Capital LLC	415,000	$2.07M	0.1%	-53.5%	1.072%
2/13/2023	Foresite Capital Management V LLC	3,585,346	$17.86M	13.9%	+7.5%	9.262%
2/10/2023	Opaleye Management Inc.	535,000	$2.66M	0.9%	+142.5%	1.382%
2/3/2023	Frazier Life Sciences Management L.P.	1,398,194	$6.96M	0.4%	N/A	3.612%
11/15/2022	Farallon Capital Management LLC	223,149	$1.29M	0.0%	-45.5%	0.576%
11/14/2022	Forefront Analytics LLC	13,065	$74K	0.0%	N/A	0.034%
8/16/2022	Woodline Partners LP	211,684	$1.17M	0.0%	-15.3%	0.547%
8/16/2022	DAFNA Capital Management LLC	81,899	$0.45M	0.1%	+2.2%	0.212%
8/15/2022	Opaleye Management Inc.	32,300	$0.18M	0.1%	N/A	0.083%
8/12/2022	Ensign Peak Advisors Inc	142,598	$0.79M	0.0%	-43.0%	0.368%
8/8/2022	Walleye Capital LLC	31,719	$0.18M	0.0%	N/A	0.082%
8/4/2022	TD Asset Management Inc.	106,948	$0.59M	0.0%	+59.3%	0.276%
5/10/2022	TD Asset Management Inc.	67,133	$0.77M	0.0%	+19.4%	0.173%
5/5/2022	New York State Common Retirement Fund	9,495	$0.11M	0.0%	+475.1%	0.025%
2/19/2022	Woodline Partners LP	250,000	$3.17M	0.0%	N/A	0.646%
2/15/2022	Laurion Capital Management LP	205,021	$2.60M	0.0%	N/A	0.530%
2/15/2022	Lynx1 Capital Management LP	409,358	$5.19M	4.5%	N/A	1.058%
2/15/2022	Adage Capital Partners GP L.L.C.	761,589	$9.66M	0.0%	N/A	1.968%
2/14/2022	Boxer Capital LLC	892,057	$11.31M	0.4%	N/A	2.305%
2/14/2022	Nextech Invest AG	611,310	$7.75M	1.8%	N/A	1.579%
2/14/2022	DAFNA Capital Management LLC	97,500	$1.24M	0.3%	N/A	0.252%
2/14/2022	Omega Fund Management LLC	711,479	$9.02M	1.3%	N/A	1.838%
2/11/2022	Foresite Capital Opportunity Management V LLC	468,820	$5.95M	4.0%	N/A	1.211%
2/11/2022	Ensign Peak Advisors Inc	250,000	$3.17M	0.0%	N/A	0.646%
2/10/2022	TD Asset Management Inc.	56,202	$0.71M	0.0%	N/A	0.145%
2/8/2022	Northern Trust Corp	96,884	$1.23M	0.0%	N/A	0.250%
1/24/2022	Strs Ohio	2,700	$34K	0.0%	N/A	0.007%

Data available starting January 2016

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Today's Range

Now: $4.06

$4.06

50 Day Range

MA: $4.06

$4.06

$4.07

52 Week Range

Now: $4.06

$2.05

$12.37

Volume

N/A

Average Volume

592,167 shs

Market Capitalization

$179.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.98

Who are the company insiders with the largest holdings of Theseus Pharmaceuticals?: Theseus Pharmaceuticals' top insider shareholders include:
Carl L Gordon (Director)
Foresite Capital Management V, (Major Shareholder)
Bradford D Dahms (CFO)
Learn More about top insider investors at Theseus Pharmaceuticals.

Financial Prophecy

From Porter & Company | Ad